Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EP300_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EP300_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EP300_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EP300_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EP300_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EP300_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190122231 | Oral cavity | NEOLP | regulation of NIK/NF-kappaB signaling | 24/2005 | 112/18723 | 6.77e-04 | 5.63e-03 | 24 |
GO:005109231 | Oral cavity | NEOLP | positive regulation of NF-kappaB transcription factor activity | 30/2005 | 152/18723 | 6.81e-04 | 5.66e-03 | 30 |
GO:006053813 | Oral cavity | NEOLP | skeletal muscle organ development | 32/2005 | 166/18723 | 7.05e-04 | 5.81e-03 | 32 |
GO:190357824 | Oral cavity | NEOLP | regulation of ATP metabolic process | 20/2005 | 87/18723 | 7.28e-04 | 5.97e-03 | 20 |
GO:000931432 | Oral cavity | NEOLP | response to radiation | 71/2005 | 456/18723 | 7.84e-04 | 6.25e-03 | 71 |
GO:005109121 | Oral cavity | NEOLP | positive regulation of DNA-binding transcription factor activity | 45/2005 | 260/18723 | 8.06e-04 | 6.39e-03 | 45 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:006151521 | Oral cavity | NEOLP | myeloid cell development | 17/2005 | 71/18723 | 1.10e-03 | 8.28e-03 | 17 |
GO:003032315 | Oral cavity | NEOLP | respiratory tube development | 33/2005 | 181/18723 | 1.58e-03 | 1.11e-02 | 33 |
GO:001908321 | Oral cavity | NEOLP | viral transcription | 13/2005 | 50/18723 | 1.85e-03 | 1.27e-02 | 13 |
GO:000751912 | Oral cavity | NEOLP | skeletal muscle tissue development | 29/2005 | 155/18723 | 1.97e-03 | 1.32e-02 | 29 |
GO:000647631 | Oral cavity | NEOLP | protein deacetylation | 21/2005 | 101/18723 | 2.11e-03 | 1.39e-02 | 21 |
GO:004346733 | Oral cavity | NEOLP | regulation of generation of precursor metabolites and energy | 25/2005 | 130/18723 | 2.65e-03 | 1.66e-02 | 25 |
GO:006054114 | Oral cavity | NEOLP | respiratory system development | 35/2005 | 203/18723 | 3.08e-03 | 1.88e-02 | 35 |
GO:003526413 | Oral cavity | NEOLP | multicellular organism growth | 25/2005 | 132/18723 | 3.27e-03 | 1.95e-02 | 25 |
GO:000975515 | Oral cavity | NEOLP | hormone-mediated signaling pathway | 33/2005 | 190/18723 | 3.53e-03 | 2.07e-02 | 33 |
GO:004354331 | Oral cavity | NEOLP | protein acylation | 40/2005 | 243/18723 | 3.85e-03 | 2.21e-02 | 40 |
GO:003032416 | Oral cavity | NEOLP | lung development | 31/2005 | 177/18723 | 4.04e-03 | 2.30e-02 | 31 |
GO:004392311 | Oral cavity | NEOLP | positive regulation by host of viral transcription | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
GO:000647331 | Oral cavity | NEOLP | protein acetylation | 34/2005 | 201/18723 | 4.76e-03 | 2.61e-02 | 34 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
EP300 | BAS | Skin | SCCIS | AC104365.1,STX18-AS1,VASN, etc. | 1.89e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Skin/Str/TF_SCCIS/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | ADJ | AL096865.1,MACF1,DDX17, etc. | 5.60e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | PTC | AL096865.1,MACF1,DDX17, etc. | 4.33e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_PTC/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ADJ | SECISBP2L,NKRF,SYNE2, etc. | 3.30e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ATC | SECISBP2L,NKRF,SYNE2, etc. | 1.17e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ATC/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EP300 | SNV | Missense_Mutation | | c.5528A>C | p.Gln1843Pro | p.Q1843P | Q09472 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EP300 | SNV | Missense_Mutation | | c.6023N>T | p.Ser2008Phe | p.S2008F | Q09472 | protein_coding | tolerated(0.06) | benign(0.203) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
EP300 | SNV | Missense_Mutation | rs769721803 | c.1349N>T | p.Ala450Val | p.A450V | Q09472 | protein_coding | tolerated(0.07) | possibly_damaging(0.771) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EP300 | SNV | Missense_Mutation | rs775556373 | c.5854N>G | p.Ile1952Val | p.I1952V | Q09472 | protein_coding | tolerated(0.33) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.4352N>C | p.His1451Pro | p.H1451P | Q09472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EP300 | SNV | Missense_Mutation | | c.4608A>T | p.Glu1536Asp | p.E1536D | Q09472 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
EP300 | SNV | Missense_Mutation | | c.2498N>T | p.Ser833Leu | p.S833L | Q09472 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.992) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.980C>T | p.Ala327Val | p.A327V | Q09472 | protein_coding | tolerated(0.08) | possibly_damaging(0.833) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
EP300 | SNV | Missense_Mutation | novel | c.2744G>T | p.Arg915Leu | p.R915L | Q09472 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
EP300 | SNV | Missense_Mutation | novel | c.1440N>A | p.Met480Ile | p.M480I | Q09472 | protein_coding | tolerated(0.54) | benign(0.076) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103579 | CURCUMIN | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103614 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-UNDECYLIDENEMALONATE | CHEMBL1797707 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 187051830 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 249565916 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-PENTADECYLIDENEMALONATE | CHEMBL404916 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103615 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103578 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-DODECYLIDENEMALONATE | CHEMBL1797708 | 21292492 |